🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 88165U109
- Market Cap
- Small Cap · $193 Million
- IPO
- 12/12/2013 · $7.00/share
Business: TetraLogic Pharmaceuticals Corp. is a leader in the discovery and development of small molecule drugs called Smac mimetics for the treatment of cancers. Smac mimetics are an entirely new class of targeted drugs that specifically induce cancer cell death and inhibit fundamental mechanisms of cancer cell survival and resistance, enabling tumors to die. TetraLogic's lead Smac mimetic drug, birinapant, is in Phase 2 clinical trials and is being developed for both solid tumors and hematological malignancies as a single agent and in combination with several standard-of-care cancer therapies.
Company Contact
- CEO
- J. Kevin Buchi
- CFO
- Pete A. Meyers
- Headquarters
- 343 Phoenixville Pike, Malvern, PA 19355
- Phone
- 610-889-9900
- Investor Relations
- Lisa Burns, Burns McClellan, Inc. · 212-213-0006 · lburns@burnsmc.com